Farglitazar
Farglitazar
Farglitazar (pronounced: far-gli-ta-zar) is a Peroxisome proliferator-activated receptor (PPAR) modulator that was under development for the treatment of Type 2 diabetes. It is a member of the Thiazolidinedione class of drugs, which are known for their insulin-sensitizing effects.
Etymology
The name "Farglitazar" is derived from the class of drugs it belongs to, the Thiazolidinediones, and its unique chemical structure. The "far" prefix is an abbreviation of "farnesoid X receptor", one of the receptors it was designed to target. The "glitazar" suffix is common among PPAR modulators, indicating its function and class.
Mechanism of Action
Farglitazar works by activating the Peroxisome proliferator-activated receptor gamma (PPARγ), a key regulator of glucose and lipid metabolism in the body. By activating PPARγ, Farglitazar enhances insulin sensitivity, leading to improved blood glucose control.
Related Terms
- Peroxisome proliferator-activated receptor: A group of nuclear receptor proteins that function as transcription factors regulating the expression of genes.
- Thiazolidinedione: A class of drugs used to treat diabetes by increasing the body's sensitivity to insulin.
- Type 2 diabetes: A chronic condition that affects the way the body processes blood sugar (glucose).
See Also
External links
- Medical encyclopedia article on Farglitazar
- Wikipedia's article - Farglitazar
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski